Medicines Articles
Results from the Phase III PROLONG9FP ongoing extension clinical development program evaluating the long-term efficacy and safety of IDELVION (coagulation factor IX [recombinant], albumin fusion protein) showed that extended prophylaxis treatment regimens effectively prevented bleeds while also reducing overall IDELVION consumption.
The U.S. Food and Drug Administration granted orphan drug designation to dusquetide (SGX942, Soligenix) for the treatment of macrophage activation syndrome.
The U.S. Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis) to treat advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy.
True North Therapeutics’ TNT009 for the treatment of autoimmune hemolytic anemia, including cold agglutinin disease (CAD), has been granted orphan drug status by the U.S. Food and Drug Administration.
Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone (a type of corticosteroid) has been approved by the U.S. Food and Drug Administration to treat individuals with multiple myeloma who have received one to three prior medications.
The Centers for Disease Control and Prevention (CDC) has released the CDC Guideline for Prescribing Opioids for Chronic Pain.
The U.S. Food and DrugAdministration approved Merck and Co.’s Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuroniumbromide and vecuronium bromide.
The U.S. Food and Drug Administration granted accelerated approval for pembrolizumab (Keytruda, Merck & Co.) for treatment of patients with advanced (metastatic)
non-small cell lung cancer.
The U.S. Food and Drug Administration has approved Baxalta’s Adynovate for use in hemophilia A patients aged 12 years and older.
The U.S. Food and Drug Administration has approved Fluad (Seqirus), an influenza vaccine that contains the adjuvant MF59.
